Oppenheimer & Co. Inc. Has $36.43 Million Stock Position in AbbVie Inc. $ABBV

Oppenheimer & Co. Inc. lessened its stake in AbbVie Inc. (NYSE:ABBV) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,447 shares of the company’s stock after selling 8,094 shares during the quarter. AbbVie makes up 0.5% of Oppenheimer & Co. Inc.’s holdings, making the stock its 29th biggest position. Oppenheimer & Co. Inc.’s holdings in AbbVie were worth $36,432,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. Centennial Wealth Advisory LLC boosted its holdings in shares of AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after buying an additional 45 shares during the last quarter. Weil Company Inc. boosted its holdings in shares of AbbVie by 2.3% in the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after buying an additional 46 shares during the last quarter. Hardin Capital Partners LLC boosted its holdings in shares of AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after buying an additional 46 shares during the last quarter. Inlet Private Wealth LLC boosted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock valued at $3,937,000 after buying an additional 47 shares during the last quarter. Finally, D.B. Root & Company LLC boosted its holdings in shares of AbbVie by 4.3% in the 3rd quarter. D.B. Root & Company LLC now owns 1,152 shares of the company’s stock valued at $267,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $211.66 on Friday. The business has a fifty day simple moving average of $214.55 and a two-hundred day simple moving average of $221.60. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81. The company has a market capitalization of $374.26 billion, a price-to-earnings ratio of 104.27, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the firm posted $2.46 EPS. The company’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, equities analysts anticipate that AbbVie Inc. will post 14.13 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. UBS Group cut their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Guggenheim raised their price target on AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a report on Friday, April 10th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $252.90.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and guidance lift — AbbVie reported Q1 revenue of $15.00B and adjusted EPS of $2.65, beat consensus on sales and raised its 2026 adjusted EPS range to $14.08–$14.28. The beat and guide raise highlight Skyrizi/Rinvoq strength and drove the initial rally. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Immunology drivers — Management and coverage note that Skyrizi and Rinvoq produced the bulk of immunology gains (Skyrizi ~$4.48B, Rinvoq ~$2.12B in the quarter), helping offset Humira’s decline and underpinning the company’s raised 2026 outlook. AbbVie hikes 2026 outlook
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms bumped ratings/targets after the quarter: Bank of America upgraded ABBV to Buy and lifted its PT to $234; Morgan Stanley and Canaccord also raised targets. These upgrades add buying interest and momentum. Bank of America Upgrades AbbVie
• Neutral Sentiment: Rinvoq label expansion filing — AbbVie has filed for an FDA label expansion of Rinvoq in alopecia areata, which, if approved, would broaden the drug’s market and is a potential medium‑term revenue tailwind. ABBV Seeks FDA Nod for Rinvoq
• Neutral Sentiment: Skyrizi competitive defense — AbbVie outlined strategies to defend Skyrizi against a new J&J psoriasis entrant (Icotyde); that competitive positioning matters for long‑term share but is not an immediate financial swing. AbbVie outlines Skyrizi defense
• Neutral Sentiment: Corporate PR / innovation outreach — AbbVie awarded the RIME Therapeutics Biotech Innovators prize in Quebec, reinforcing R&D partnerships and local innovation efforts (long‑term strategic benefit). AbbVie and adMare Announce RIME Therapeutics Award
• Negative Sentiment: Pipeline pruning — AbbVie said it would discontinue a cancer candidate, a near‑term negative for pipeline optionality that could concern investors focused on long‑term oncology upside. AbbVie tops Q1, discontinues cancer candidate
• Negative Sentiment: Analyst estimate trimming & insider selling — Some shops (Erste) trimmed FY estimates slightly and public filings show recent insider sales; both are modest headwinds that can amplify short‑term volatility. (internal/market data sources)

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by company insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.